Classical markers like ER and ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: results from the GEICAM/2002-01 phase II study.

doi:10.1007/s12094-012-0820-4

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Classical markers like ER and ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: results from the GEICAM/2002-01 phase II study.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 1 Jun 2012

Sánchez-Rovira Pedro, Antón Antonio, Barnadas Agustí, Velasco Amalia, Lomas María, Rodríguez-Pinilla María, Ramírez José Luis, Ramírez César, Ríos María José, Castellá Eva, García-Andrade Carmen, San Antonio Belén, Carrasco Eva, Palacios José Luis

Abstract excerpt

INTRODUCTION: The identification and validation of biomarkers of chemotherapy sensitivity is critical in order to individualise therapy in breast cancer. We evaluated pathological complete response (pCR) to GAT, and its correlation with tumour biomarkers before and after neoadjuvant chemotherapy....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Deoxycytidine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Doxorubicin

Share to Gemcitabine

Share to Inhibitor of Apoptosis Proteins

Share to Ki-67 Antigen

Share to Neoadjuvant Therapy

Share to Paclitaxel

Share to Survivin

Source

Open in PubMed

Identifiers

PMID: 22634531
DOI: 10.1007/s12094-012-0820-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22634531-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Classical markers like ER and ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: results from the GEICAM/2002-01 phase II study.PMID 22634531Read ↗

Evaluation of biological pathways involved in chemotherapy response in breast cancer.Semantic proximity Read ↗

Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials.Semantic proximity Read ↗

Unearthing New Genomic Markers of Drug Response by Improved Measurement of Discriminative PowerSemantic proximity Read ↗

A bad tumor biomarker is as bad as a bad drug: The gap between genomics data and phenotype to predict response.Semantic proximity Read ↗

Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients.Semantic proximity Read ↗

Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer.Semantic proximity Read ↗

Palbociclib in endocrine-resistant metastatic breast cancer patients: gene polymorphism- based study.Semantic proximity Read ↗

mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.